ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered into a strategic partnership with fellow Chinese firm Yangtze River Pharmaceutical (Group) Co., Ltd. This collaboration aims to strengthen and enhance the development of ImmuneOnco’s investigational pipeline programs.
The partnership encompasses a wide range of activities, including long-term collaboration in drug research and development, innovative drug development, pharmaceutical production, sales, talent exchange, training, technical support, consulting services, investment, financing, and mergers and acquisitions. A key focus of the collaboration will be on the development of hyaluronidase for subcutaneous drug delivery. Financial details of the agreement have not been disclosed.- Flcube.com
